A citation-based method for searching scientific literature

John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
Times Cited: 92



Mark S Fineman, Thomas A Bicsak, Larry Z Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain D Baron. Diabetes Care 2003
Times Cited: 264




List of shared articles



Times cited

Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.
Dan Zheng, Viorica Ionut, Vahe Mooradian, Darko Stefanovski, Richard N Bergman. Diabetes 2009
31

Glycaemic control in type 2 diabetes: targets and new therapies.
Abd A Tahrani, Milan K Piya, Amy Kennedy, Anthony H Barnett. Pharmacol Ther 2010
104

The GLP-1 system as a therapeutic target.
C Mark B Edwards. Ann Med 2005
12

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
Claudio González, Valeria Beruto, Guillermo Keller, Silvina Santoro, Guillermo Di Girolamo. Expert Opin Investig Drugs 2006
20

Exenatide: a new option for the treatment of type 2 diabetes.
Bong Kyu Yoo, Darren Michael Triller, Dong Joo Yoo. Ann Pharmacother 2006
24


Targeting postprandial hyperglycemia.
Marc S Rendell, Lois Jovanovic. Metabolism 2006
50


Is exenatide a useful addition to diabetes therapy?
Nasser E Mikhail. Endocr Pract 2006
4

Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.
Abd A Tahrani, Milan K Piya, Anthony H Barnett. Expert Rev Endocrinol Metab 2008
2

Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.
A Sharma, A Sörenby, A Wernerson, S Efendic, M Kumagai-Braesch, A Tibell. Diabetologia 2006
33

Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus.
Curtis Triplitt, Ralph A DeFronzo. Expert Rev Endocrinol Metab 2006
16


Glucagon and glucagon-like peptide receptors as drug targets.
J L Estall, D J Drucker. Curr Pharm Des 2006
67

Exenatide.
Anthony H Barnett. Drugs Today (Barc) 2005
19

Alogliptin: a new addition to the class of DPP-4 inhibitors.
Radha Andukuri, Andjela Drincic, Marc Rendell. Diabetes Metab Syndr Obes 2009
25